Page 556 - Clinical Immunology_ Principles and Practice ( PDFDrive )

534 Part four Immunological Deficiencies

5. Freeman AF, Marciano BE, Anderson VL, et al. Corticosteroids in the 30. Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in
treatment of severe Nocardia pneumonia in chronic granulomatous patients with cryptococcal meningitis. J Immunol 2013;190:3959–66.
disease. Pediatr Infect Dis J 2011;30:806–8. 31. Allison AC. Immunosuppressive drugs: the first 50 years and a glance
6. Leiding JW, Freeman AF, Marciano BE, et al. Corticosteroid therapy for forward. Immunopharmacology 2000;47:63–83.
liver abscess in chronic granulomatous disease. Clin Infect Dis 32. Mueller NJ. New immunosuppressive strategies and the risk of infection.
2012;54:694–700. Transpl Infect Dis 2008;10:379–84.
7. Freeman AF, Holland SM. Antimicrobial prophylaxis for primary 33. Halloran PF. Immunosuppressive drugs for kidney transplantation. N
immunodeficiencies. Curr Opin Allergy Clin Immunol 2009;9:525–30. Engl J Med 2004;351:2715–29.
8. Rondeau S, Couderc L, Dominique S, et al. High frequency of 34. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for
voriconazole-related phototoxicity in cystic fibrosis patients. Eur Respir J the use of antimicrobial agents in neutropenic patients with cancer: 2010
2012;39:782–4. update by the Infectious Diseases Society of America. Clin Infect Dis
9. Tarlock K, Johnson D, Cornell C, et al. Elevated fluoride levels and 2011;52:e56–93.
periostitits in pediatric hematopoietic stem cell transplant recipients 35. Kang I, Park SH. Infectious complications in SLE after
receiving long-term voriconazole. Pediatr Blood Cancer 2015;62:918–20. immunosuppressive therapies. Curr Opin Rheumatol 2003;15:528–34.
10. Boztug K, Klein C. Genetic etiologies of severe congenital neutropenia. 36. Gaber AO, Knight RJ, Patel S, et al. A review of the evidence for use of
Curr Opin Pediatr 2011;23:21–6. thymoglobulin induction in renal transplantation. Transplant Proc
11. Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. Curr Opin 2010;42:1395–400.
Allergy Clin Immunol 2015;15:104–9. 37. Salvana EM, Salata RA. Infectious complications associated with
12. Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human monoclonal antibodies and related small molecules. Clin Microbiol Rev
dendritic-cell immunodeficiency. N Engl J Med 2011;365:127–38. 2009;22:274–90.
13. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell 38. Koo S, Marty FM, Baden LR. Infectious complications associated with
immunodeficiencies: comparisons and contrasts. Annu Rev Immunol immunomodulating biologic agents. Infect Dis Clin North Am
2009;27:199–227. 2010;24:285–306.
14. Cuccherini B, Chua K, Gill V, et al. Bacteremia and skin/bone infections 39. Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor
in two patients with X-linked agammaglobulinemia caused by an unusual necrosis factor–α blocker therapy: a retrospective analysis of 98 cases.
organism related to Flexispira/Helicobacter species. Clin Immunol Clin Infect Dis 2015;61:409–17.
2000;97:121–9. 40. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol
15. Murray PR, Jain A, Uzel G, et al. Pyoderma gangrenosum-like ulcer in a 2010;47:187–98.
patient with X-linked agammaglobulinemia: identification of Helicobacter 41. www.accessdata.fda.gov/drugsatfda_docs/
bilis by mass spectrometry analysis. Arch Dermatol 2010;146:523–6. label/2012/103705s5367s5388lbl.pdf.
16. Van der Burg M, Gennery AR. Educational paper: the expanding clinical 42. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in
and immunological spectrum of severe combined immunodeficiency. Eur pediatric autoimmune and inflammatory CNS disease. Neurology
J Pediatr 2011;170:561–71. 2014;83:142–50.
17. Kobrynski LI, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: 43. Bloomgren G, Richman S, Hotermans S, et al. Risk of
the chromosome 22q11.2 deletion syndromes. Lancet 2007;1443–52. natalizumab-associated progressive multifocal leukoencephalopathy. N
18. Perez EE, Bokszczanin A, McDonald-McGinn D. Safety of the live viral Engl J Med 2012;366:1870–80.
vaccines in patients with chromosome 22q11.2 deletion syndrome 44. Piperdi B, Ling Y, Liebes L, et al. Bortezomib: understanding the
(DiGeorge/velocardiofacial syndrome). Pediatrics 2003;112:e325. mechanism of action. Mol Cancer Ther 2011;10:2029–30.
19. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H) 17 cell 45. Fishman JA, Issa NC. Infection in organ transplantation: risk factors and
differentiation in subjects with autosomal dominant hyper-IgE syndrome. evolving patterns of infection. Infect Dis Clin North Am 2010;24:273–83.
Nature 2008;452:773–6. 46. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after
20. Freeman AF, Holland SM. Clinical manifestations, etiology, and allogeneic hematopoietic-cell transplantation. N Engl J Med
pathogenesis of the hyper-IgE syndromes. Pediatr Res 2009;65:32R–37R. 2010;363:2091–101.
21. Odio CD, Milligan KL, McGowan K, et al. Endemic mycosis in patients 47. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation:
with STAT3-mutated hyper IgE (Job) syndrome. J Allergy Clin Immunol an overview of infection risks and epidemiology. Infect Dis Clin North
2015;136:1411–13. Am 2010;24:257–72.
22. Zhang Q, Davis J, Lamborn IT, et al. Combined immunodeficiency 48. Humar A, Snydman D. Cytomegalovirus in solid organ transplant
associated with DOCK8 mutations. N Engl J Med 2009;361:2046–55. recipients. Am J Transplant 2009;9:S78–86.
23. Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian 49. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic
susceptibility to mycobacterial diseases. J Allergy Clin Immunol stem cell transplant recipients. Infect Dis Clin North Am 2010;24:319–37.
2008;122:1043–51. 50. Kotton CN, Kumar D, Caliendo AM, et al. Updated International
24. Holland SM. Interferon gamma, IL-12, IL-12R and STAT1 Consensus Guidelines on the management of cytomegalovirus in
immunodeficiency diseases: disorders of the interface of innate and solid-organ transplantation. Transplantation 2013;96:333–60.
adaptive immunity. Immunol Res 2007;38:342–6. 51. Nucci M, Anaissie E. Fungal infections in hematopoietic stem cell
25. Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function transplantation and solid-organ transplantation—focus on aspergillosis.
mutations underlie an unexpectedly broad clinical phenotype: an Clin Chest Med 2009;30:295–306, vii.
international survey of 274 patients from 167 kindreds. Blood 52. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for
2016;127:3154–64. the management of candidiasis: 2016 update by the Infectious Diseases
26. Ram S, Lewis LA, Rice PA. Infections of people with complement Society of America. Clin Infect Dis 2016;62:e1–50.
deficiencies and patients who have undergone splenectomy. Clin 53. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent
Microbiol Rev 2010;23:740–80. cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J
27. Browne SK, Holland SM. Anticytokine autoantibodies in infectious Med 2013;369:1227–36.
diseases: pathogenesis and mechanisms. Lancet Infect Dis 2010;10:875–85. 54. Chemaly RF, Ullmann AJ, Stoelben S. Letermovir for cytomegalovirus
28. Kisand K, Boe Wolff AS, Podkrajsek KT. Chronic mucocutaneous prophylaxis in hematopoietic-cell transplantation. N Engl J Med
candidiasis in APECED or thymoma patients correlate with autoimmunity 2014;370:1781–9.
to Th17 associated cytokines. J Exp Med 2010;207:299–308. 55. O’Reilly RJ, Prockop S, Hasan AN, et al. Virus-specific T-cell banks for
29. Puel A, Doffinger R, Natividad A, et al. Autoantibodies against IL-17A, “off the shelf” adoptive therapy of refractory infections. Bone Marrow
IL-17F, and Il-22 in patients with chronic mucocutaneous candidiasis and Transplant 2016;51:1163–72.
autoimmune polyendocrine syndrome type 1. J Exp Med 2010;207:291–7.